Welcome to our dedicated page for Connect Biopharma Holdings SEC filings (Ticker: CNTB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Connect Biopharma Holdings Limited filings document regulatory disclosures for a Cayman Islands clinical-stage biopharmaceutical issuer developing rademikibart for inflammatory diseases. Recent Form 8-K reports cover operating and financial results, clinical and regulatory updates tied to rademikibart, and Regulation FD disclosures.
The filing record also includes governance and capital-structure matters, including board composition, insider purchase disclosures, material agreements, ADR-program and deposit-agreement disclosures, and the relationship between American depositary shares and ordinary shares. These filings frame the company’s emerging-growth-company status, public-company reporting obligations and risk-related clinical development disclosures.
Connect Biopharma Holdings Limited entered a securities purchase agreement for a private placement of 6,130,000 ordinary shares at $3.25 per share, raising approximately $20.2 million in gross proceeds. The company plans to use the funds for clinical R&D, other development programs, working capital and general corporate purposes, and now expects its cash resources to fund operations into the second half of 2027.
The 8-K also highlights positive topline Phase 1 data for intravenous rademikibart in asthma and COPD, where a single 300 mg 2-minute IV push produced rapid and clinically meaningful FEV1 improvements of about 200–400 mL maintained through Day 29 with a favorable safety profile. In addition, partner Simcere reported Phase 3, 52-week results in atopic dermatitis, with high proportions of patients achieving deep skin clearance endpoints and safety comparable to placebo, supporting rademikibart’s potential as a best-in-class IL‑4Rα antibody.
Connect Biopharma Holdings Ltd director James Huang filed an initial Form 3 showing indirect exposure to the company’s Ordinary Shares. The filing reports that Panacea Venture Healthcare Fund II, L.P. is the record holder of 12,000,000 Ordinary Shares, with Huang linked through a chain of ownership interests in related entities. The footnote explains that Huang may be deemed to share beneficial ownership of these shares but expressly disclaims such beneficial ownership, indicating the position is held at the fund level rather than as a direct personal holding.
Connect Biopharma Holdings Ltd president David Leslie Szekeres filed an initial Form 3 reporting his equity holdings in the company. He directly holds 215,739 ordinary shares and several employee stock option grants over ordinary shares with exercise prices of $1.77, $0.97, and $2.69, expiring between 2034 and 2035. The footnotes explain that these options vest over four years, with portions vesting on the first anniversary of grant and the remainder vesting monthly thereafter, contingent on his continued service.
Connect Biopharma Holdings Ltd Chief Executive Officer Barry D. Quart filed an initial ownership report showing a mix of stock options and ordinary shares. He holds employee stock options over 2,658,734, 432,392, and 700,000 ordinary shares with exercise prices of $1.77, $0.97, and $2.69, expiring between 2034 and 2035. The options vest over four years, with portions vesting on the first anniversary of grant and the balance vesting monthly thereafter, subject to continuous service. Quart also reports direct ownership of 95,147 ordinary shares and indirect ownership of 128,887 ordinary shares through a joint account with his spouse.
Connect Biopharma Holdings Ltd executive Lisa Peraza, Senior Vice President of Finance, filed an initial ownership report showing her equity position in the company. She directly holds 45,189 Ordinary Shares.
She also holds several employee stock options over Ordinary Shares, including 400,000 shares at $1.15 per share expiring on August 12, 2034, 55,318 shares at $0.97 expiring on December 26, 2034, 40,000 shares at $1.14 expiring on July 7, 2035, and 250,000 shares at $2.69 expiring on December 26, 2035. Footnotes state these options generally vest over four years, with either a 25% cliff after one year followed by monthly vesting, or monthly vesting over four years, in each case requiring continued service.
Connect Biopharma Holdings Ltd director Kleanthis Gabriel Xanthopoulos filed an initial statement of beneficial ownership. He reports holding 80,000 Ordinary Shares directly, plus several stock options to buy Ordinary Shares with exercise prices between $0.96 and $8.16, expiring from 2030 to 2036. One option series is fully vested and exercisable, while another fully vests and becomes exercisable on March 2, 2027.
Connect Biopharma Holdings Ltd director Karen J. Wilson reported her equity holdings in the company. The filing lists stock options over multiple blocks of Ordinary Shares, including rights to buy 89,220 shares at an exercise price of $8.1600 per share expiring on November 1, 2030, alongside additional options at exercise prices of $4.1200, $1.2700, $1.1800, $0.9600, and $2.5000 with expirations between March 1, 2032 and March 2, 2036. She also directly holds 10,000 Ordinary Shares. Footnotes state that one option grant is fully vested and exercisable, and another will fully vest and become exercisable on March 2, 2027.
Connect Biopharma Holdings Ltd director James A. Schoeneck reported his initial beneficial ownership of stock options. He holds options to purchase 120,000 ordinary shares at an exercise price of $2.38 per share, expiring on July 22, 2035, which vest over three years.
He also holds options to purchase 60,000 ordinary shares at an exercise price of $2.50 per share, expiring on March 2, 2036, which fully vest on March 2, 2027. The filing lists these derivative holdings and does not show any buy or sell transactions.
Connect Biopharma Holdings Ltd director Jean I Liu filed an initial ownership report detailing several stock options over Ordinary Shares. The options have exercise prices that include $22.29, $4.12, $1.27, $1.18, $0.96 and $2.50, with expiration dates ranging from 2031 through 2036.
The filing notes that one stock option is already fully vested and exercisable, while another will fully vest and become exercisable on March 2, 2027. The report lists holdings only and does not show any purchases or sales.
Connect Biopharma Holdings Ltd filing reports that BioFortune Inc. and Wubin Pan reported beneficial ownership of Ordinary Shares as of December 31, 2025. The filing shows 5,987,431 shares held of record by BioFortune Inc. (representing 10.7% of the class) and 6,026,813 shares attributable to Wubin Pan (representing 10.8% of the class), based on 55,903,513 Ordinary Shares outstanding as of October 31, 2025. The statement discloses that Mr. Pan is the sole shareholder of BioFortune Inc. and therefore shares beneficial ownership of the shares held by that entity; shared voting and dispositive power amounts are provided in the filing.